EMA Chief: ‘Safety Is Our Priority’ In Review Of COVID-19 Vaccine
Data To Be Made Available Quickly After Approval
The EMA says its experts are working “around the clock” on a recommendation for conditional marketing authorization of a COVID-19 vaccine, but that it will only OK a vaccine if it is satisfied that the evidence convincingly shows the benefits are greater than the risks.
You may also be interested in...
European parliamentarians have defended the formal marketing authorization approach being taken by the EU, saying “safety is of the utmost importance” if there is to be trust in coronavirus vaccines.
The cyberattack on coronavirus vaccine data held by the European Medicines Agency is the latest in a string of hacks that are also targeting organizations involved with the cold chain distribution of vaccines.
Individuals with history of significant allergic reactions are now being told not to have the vaccine after warnings were not included in healthcare professional information.